Argenta and Loyal collaborate on investigational lifespan-extension therapeutic for large-breed dogs
The global animal health industry is witnessing growing interest in canine longevity research, with Argenta and biotechnology company Loyal announcing a strategic development partnership to advance LOY-003, an investigational therapeutic candidate designed to extend the lifespan of large- and giant-breed dogs.
Announced on November 16, 2026, the collaboration brings together Argenta’s animal health contract development, research and manufacturing capabilities with Loyal’s specialised focus on canine ageing biology.
The agreement represents another step in the emergence of longevity as a potential therapeutic category within companion animal medicine.
Understanding LOY-003: Targeting the biology of canine ageing
LOY-003 is being developed as a daily oral medication for large- and giant-breed dogs. The scientific rationale is linked to the relationship between body size, growth-related hormonal signalling and lifespan in dogs. Two important biological pathways are central to the programme:
-
Growth hormone (GH)
-
Insulin-like growth factor 1 (IGF-1)
Large-breed dogs generally have shorter average lifespans than smaller breeds. Differences in growth trajectories and growth-related endocrine signalling are among the biological factors being investigated to understand this relationship. LOY-003 aims to modulate growth hormone and IGF-1-related biology in adult dogs.
The underlying objective is to investigate whether modifying these pathways can improve longevity without compromising the animal’s overall health and quality of life. Importantly, LOY-003 remains investigational. Its proposed lifespan-extension benefits have not been established as a clinically proven outcome or as an approved veterinary indication.
Argenta brings development and manufacturing expertise
Under the partnership, Argenta will support the early development of LOY-003, with the possibility of expanding its involvement as the programme progresses.
Argenta operates as an animal-health-focused contract development, research and manufacturing organisation (CDRMO). Its integrated capabilities include:
-
Pharmaceutical formulation development
-
Manufacturing process development
-
Analytical development and testing
-
Regulatory and technical support
-
Clinical trial supply
-
Commercial manufacturing capabilities
The company’s Molecule to Market model is designed to support animal health innovators across multiple stages of pharmaceutical development. Its US development and manufacturing operations in Shawnee, Kansas, provide capabilities in sterile fill-finish, non-sterile liquids and pastes, and oral solid dosage forms.
For a programme such as LOY-003, formulation development, manufacturing consistency, product stability and regulatory-quality documentation will be important as development advances.
Why canine longevity is emerging as a major veterinary opportunity
The companion animal pharmaceutical industry has historically focused on disease treatment, infection control, pain management, dermatology, oncology and chronic disease management.
Longevity therapeutics introduce a different commercial and clinical proposition: intervening in biological processes associated with ageing before the development of multiple age-related conditions. This approach is particularly relevant to dogs because:
-
Ageing is associated with increasing multimorbidity
-
Large breeds have distinctive lifespan patterns
-
Pet owners increasingly seek preventive and proactive veterinary care
-
Owners are willing to invest in interventions that improve their animals’ quality of life


